How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health The company’s lead investigational candidate, CNM-Au8(R), is currently in development as a disease-modifying treatment for people living with specific types of neurodegenerative disorders (“ND”), namely amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”) Neurodegenerative disorders are characterized by neurodegeneration – the progressive loss of neuron structure, neuronal functions, and finally, the neurons themselves Nanotherapeutics are in development to stop or reverse neurodegeneration using novel approaches to address the mitochondrial deficits and bioenergetic crises…